Crunching The Numbers: Analyzing Crispr Therapeutics' Upcoming Quarterly Earnings Report

Greetings, fellow investors! Welcome back to ShareTreck. I'm Raj, today I am going to share my thoughts around Crispr Therapeutics and their impending quarterly earnings release. I am optimistic as I want to see Casgevy earnings and sales projections. Updates on progress of all pipeline items especially wholly owned oncology and autoimmune candidates and idea of how close we may be to monetizing any of these key candidates.

Well this is my personal opinion, not financial advice.

JOIN THE CHANNEL AS A MEMBER:

Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.


The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.

[davidbest]

For the current fiscal year, the consensus earnings estimate of -$5.52 points to a change of -184.5% from the prior year. Over the last 30 days, this estimate has changed -0.1%.

For the next fiscal year, the consensus earnings estimate of -$4.45 indicates a change of +19.4% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed +0.2%.

[davidbest]

All non profit making stocks will plummet over next 12-18 months…

[sb]

Vertex earnings were very promising. Vertex CFO mentioned that the increase in their SG&A of $281 MM was primarily driven by CASGEVY. It means they are scaling up rapidly. Total active treatment centers went from 25 in Jan to 35 now and will be at 75 by year end.

[georgemathai]

Vertex claims to have collected from 20 patients on their last call.

[davidbest]

This company is expected to post quarterly loss of $1.37 per share in its upcoming report, which represents a year-over-year change of -39.8%.

Revenues are expected to be $8.39 million, down 88% from the year-ago quarter.

[davidbest]

Back down to 25-14 if as we enter bear market…

[axolotl]

Account will be ZEROED in mid August, or I will be super rich in one week, or rich in two weeks.
With the rich direction being less likely...